|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A53T SNCA carriers with Parkinson's disease showed a loss of striatal [<sup>123</sup>I]FP-CIT-specific binding ratio compared with healthy controls (p<0·0001).
|
31229470 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The utility of the combined use of <sup>123</sup>I-FP-CIT SPECT and neuromelanin MRI in differentiating Parkinson's disease from other parkinsonian syndromes.
|
29804474 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
F-FP-CIT PET and MRI are not helpful in distinguishing CBD from idiopathic Parkinson disease.
|
30371594 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Semiquantitative <sup>123</sup>I-FP-CIT SPECT striatal evaluation combined with SVM represents a promising approach to disentangle PD from non-degenerative conditions and from atypical PS at the early stage.
|
31037416 |
2019 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We aimed to determine the association between the annual changes in dopamine transporter (DAT) availability as measured by ¹²³I-ioflupane (¹²³I-FP-CIT) single-photon-emission computed tomography and single-nucleotide polymorphisms (SNPs) known to be risk factors in Parkinson's disease (PD).
|
30618224 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both PD and DLB patients had lower striatal <sup>123</sup>I-FP-CIT BRs than healthy controls for the bilateral caudate head (PD-left: F(1,29) = 28.778, P < .001, ω<sup>2</sup> = 0.35; right: F(1,29) = 35.338, P < .001, ω<sup>2</sup> = 0.42; DLB-left: F(1,29) = 28.241, P < .001, ω<sup>2</sup> = 0.31; right: F(1,29) = 18.811, P < .001, ω<sup>2</sup> = 0.26) and bilateral posterior putamen (PD-left: F(1,29) = 107.531, P < .001, ω<sup>2</sup> = 0.77; right: F(1,29) = 87.525, P < .001, ω<sup>2</sup> = 0.72; DLB-left: F(1,29) = 39.910, P < .001, ω<sup>2</sup> = 0.48; right: F(1,29) = 26.882, P < .001, ω<sup>2</sup> = 0.38).
|
30884365 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
It has excellent resolution compared with I-beta-CIT SPECT and is widely used clinically for the evaluation of Parkinson disease.
|
30672761 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>123</sup>I-FP-CIT SPECT was able to measure longitudinal reductions in raphe serotonin transporter availability in the early phases of Parkinson's disease.
|
30981664 |
2019 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Approximately 634 patients with drug-naive PD who underwent F-FP-CIT PET scans were followed up for at least 2 years.
|
30153150 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Background Both neuromelanin-sensitive magnetic resonance imaging (NmMRI) and <sup>123</sup>I-FP-CIT single photon emission computed tomography (SPECT) (DaTSCAN) assist the diagnosis of Parkinson's disease (PD).
|
28743197 |
2018 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, patients underwent neurophysiological (autonomic tests and nerve conduction studies) and neuroimaging (brain MRI, <sup>123</sup>I-FP-CIT SPECT, and <sup>123</sup>I-MIBG myocardial scintigraphy) studies, as well as a genetic analysis of 34 genes and single nucleotide polymorphisms associated with PD.
|
29943201 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The <sup>123</sup>I-FP-CIT uptake ratios in the 11 patients with iRBD and NH loss (mean, 2.48 ± 0.44) were significantly lower than those in healthy subjects (mean, 3.37 ± 0.47; P < .001) but higher than those in patients with PD (mean, 1.80 ± 0.33; P < .001).
|
29232183 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study shows that higher levels of anxiety in patients with PD are associated with lower thalamic <sup>123</sup>I-FP-CIT binding, pointing towards a contribution of serotonergic degeneration to anxiety symptoms in PD.
|
28899958 |
2018 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To clarify this issue we analyzed the clinical and 123I-FP-CIT SPECT data of a large cohort of early Parkinson's disease patients enrolled in the PPMI study.
|
29503156 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Head-to-head comparison of <sup>18</sup> F-FP-CIT and <sup>123</sup> I-FP-CIT for dopamine transporter imaging in patients with Parkinson's disease: A preliminary study.
|
29486515 |
2018 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease.
|
30288781 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed at examining sensitivity of combined visual and semi-quantitative <sup>123</sup>I-FP-CIT SPECT analyses in a prospective cohort of subjects with DLB and degenerative parkinsonisms - Parkinson's disease (PD), multiple system atrophy (MSA), corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) to determine prevalence and clinical significance of scans without evidence of dopaminergic deficit (SWEDD).
|
29406901 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Normal FP-CIT SPECT or PD characteristic reduction was confirmed by follow-up SPECT in all cases (n = 58).
|
28574876 |
2017 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This was a prospective, 54-week, comparative pilot study, in which twenty subjects with de novo PD were randomly assigned to DaTSCAN either immediately upon diagnosis (and again at 6 and 12 months) or delayed to 6 months (and again at 12 months).
|
28339403 |
2017 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Visual and semi-quantitative assessments of <sup>123</sup>I-FP-CIT single-photon emission computed tomography (SPECT) are useful for the diagnosis of dopaminergic neurodegenerative diseases (dNDD), including Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy, multiple system atrophy, and corticobasal degeneration.
|
28389938 |
2017 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
62Cu-ATSM PET with 123I-FP-CIT SPECT correction would be a promising tool to evaluate dopaminergic neuronal oxidative stress in PD.
|
28848099 |
2017 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Correlations between dopamine transporter density measured by <sup>123</sup>I-FP-CIT SPECT and regional gray matter volume in Parkinson's disease.
|
29063467 |
2017 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To examine whether combined use of <sup>123</sup>I-FP-CIT dopamine transporter single photon emission computed tomography (DAT-SPECT) and <sup>123</sup>I-MIBG myocardial scintigraphy (MIBG) is superior to either modality alone for diagnosing Parkinson's disease (PD).
|
28320195 |
2017 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> In the ROI analyses, extrastriatal <sup>123</sup>I-FP-CIT binding ratios in the hypothalamus were significantly lower in PSP than in MSA-C patients, and we observed significantly lower striatal <sup>123</sup>I-FP-CIT binding ratios in the caudate nucleus of PSP patients than in that of both PD and MSA-C patients.
|
27856628 |
2017 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The differential diagnosis between patients with essential tremor (ET) and those with Parkinson's disease (PD) whose main manifestation is tremor may be difficult unless using complex neuroimaging techniques such as 123I-FP-CIT SPECT.
|
28841694 |
2017 |